(Alliance News) - The board of directors of Arterra Bioscience Spa on Friday approved the draft financial statements for the year ended Dec. 31, which closed with a net profit for 2023 of about EUR1.1 million -- or 22 percent of the value of production -- down 24 percent from 2022. The board proposed a dividend of EUR0.1 per ordinary share, confirming the previous year's amount.

Production value decreased from EUR5.3 million to EUR5.0 million.

Ebitda realized in 2023 was about EUR1.6 million - with Ebitda margin of more than 32 percent - registering a decrease of more than 25 percent compared to 2022.

Ebit was positive EUR1.3 million, down 27% from 2022.

Net financial position was positive EUR5.7 million, compared to EUR5.5 million as of December 31, 2022.

Arterra Bioscience closed Thursday evening's session in the green by 2.0 percent at EUR2.00 per share.

By Maurizio Carta, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.